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Abstract: An increasing body of research has focused on isolating factors that predict or alter individual
differences in the behavioral and neural processes mediating the effects of abused drugs. Within this
framework, the current report assessed individual differences and the locomotor effect of nicotine. Rats
were screened for activity induced by a novel environment. Rats, which were more active to initial
environment exposure, remained more active even after seven additional 30-min exposures to the same
environment. Treatment with nicotine-di-D tartrate (1 mg/kg, sc) disrupted this effect. This nicotine
disruption of individual differences occurred whether nicotine suppressed locomotor activity (initial
administration) or stimulated locomotor activity (seventh and eighth administration). Mecamylamine (1
mg/kg), but not hexamethonium (10 mg/kg), completely blocked the suppressant and stimulant effects
of nicotine. Further, mecamylamine restored the nicotine-induced disruption of individual differences;
hexamethonium had no effect. This data pattern suggests that the disruptive effects of acute and chronic
nicotine on individual differences were mediated by neural nicotinic acetylcholine (nACh) receptors.
Keywords: Dopamine, Hexamethonium, Locomotor sensitization, Nicotinic acetylcholine, Novelty, Stress

Reactivity to a novel environment has served as a predictive variable in recent drug abuse studies (see Refs. [9,31
] for reviews). This predictive value is another reason for
the recent interest in novelty-induced activity. For instance,
rats that are more activated by exposure to a novel environment (HR) more readily self-administer amphetamine and
are more sensitive to the locomotor-stimulant effects of amphetamine [29]. Novelty-induced activity has been found to
also predict such behavioral effects as activity induced by
cocaine and caffeine [16], ethanol-induced activity and ethanol self-administration [14,15], amphetamine-conditioned
hyperactivity to contextual stimuli [17], cueing effects of
amphetamine [13] and amphetamine barpress suppressant
effects [6].
Another factor contributing to the interest in novelty-induced activity is the potential insight it may provide into the
behavioral and neural substrates underlying individual differences in drug abuse vulnerability. This idea is based, in part,
on the assumption that the predictive relation just described
likely reflects an overlap in the mechanism(s) responsible

Rats exposed to a small inescapable environment are more
active when the environment is novel than when it is familiar
(Refs. [23,33]; see later). Recently, the empirical and theoretical interest in the behavioral activating effect of novelty has increased. This interest is driven, in part, by evidence indicating
that reactivity to a novel environment is a behavioral measure
of a rat’s sensitivity to stress. Rats exposed to a novel environment show an increase in plasma levels of the “stress hormone”
corticosterone (e.g., Ref. [25]). Importantly, novelty-induced
increases in corticosterone are greater in rats that display more
locomotor activity to an inescapable novel environment [29].
Moreover, rats more activated by exposure to a novel environment [often termed high responders (FIR)] displayed a greater
increase in corticosterone levels to restraint stress than rats that
were less reactive to the novel environment [low responders
(LR)]. HR also had a more prolonged increase in corticosterone
to this restraint than LR [10]. This work is important because it
demonstrates that a purported behavioral measure of stress sensitivity (i.e., novelty-induced activity) predicts the response to
another form of stress (i.e., restraint).
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for an individual’s sensitivity to novelty and abused drugs
[9,29,31]. Indeed, there is strong empirical evidence to support this assumption. For instance, acute and chronic locomotor effects of amphetamine in rats are enhanced when
drug administration occurs in a novel rather than a familiar
environment [3,4]. Similar enhancement of drug responses
occurs when rats are exposed to stressors other than a novel
environment (e.g., Refs. [1,24,30]).
Much of the individual-differences research in rats has
used amphetamine as the prototypical psychomotor stimulant.
Individual differences and the psychomotor effects of nicotine have received much less empirical attention (see Refs.
[28,35]). Thus, one major goal of the present report was to
elucidate the relation between novelty-induced activity and
the subsequent acute and chronic locomotor effects of ( –)nicotine-di-D tartrate. Acute nicotine can produce a biphasic
effect on locomotor activity. Depending on such factors as
dose and apparatus, nicotine initially suppresses locomotor
activity in rats [7,36,37]. Chronically, nicotine tends to stimulate activity [7,19,20]. There have been past reports of a predictable relation between a rat’s nondrugged activity level in
a novel environment and its later sensitivity to the locomotor
effects of nicotine. Rats classified as HR appeared more sensitive to the locomotor-depressant effects of nicotine; LR appeared more sensitive to the stimulant effects of nicotine (e.g.,
Ref. [34]). Although this outcome is empirically interesting, it
is susceptible to a baseline-dependency interpretation [11,28].
That is, HR may have shown greater sensitivity to the locomotor-suppressant effects of nicotine simply because their baseline activity was higher in the novel environment. Similarly,
LR likely showed a larger relative increase in activity because
their activity was initially lower.
In the present report, we sought to examine whether reactivity to novelty was related to the later sensitivity of acute
and chronic nicotine using an experimental protocol more
comparable to recent individual differences research with other drugs of abuse (cf. Refs. [6,16,29]; see Section 1.4). To do
so, we had rats that were repeatedly treated with ( –)-nicotinedi-D tartrate and an injection-matched saline control. Further,
we assessed individual differences in a manner that was much
less susceptible to a baseline-dependency interpretation (i.e.,
z-score transformation; see later). A second major goal of the
present study was to determine whether the central and peripheral nicotinic acetylcholine (nACh) receptor antagonist mecamylamine or the peripheral nACh receptor antagonist hexamethonium affected individual differences in nicotine-treated
rats. That is, does novelty-induced activity predict sensitivity
to antagonism of the acute and/or chronic effects of nicotine?
No one has assessed individual differences in the sensitivity
to nACh receptor antagonism of the effect of nicotine. Indeed,
there are relatively little individual differences research on the
sensitivity to receptor antagonism whether the animal has or
has not been treated with a drug of abuse [8]. This technique
is an overlooked tool for identifying the processes mediating
individual differences.

B EVINS & B ESHEER

IN

P HYSIOLOGY & B EHAVIOR 72 (2001)

1. Methods
1.1. Animals
The animals were 134 male Sprague-Dawley rats (mean
body weight = 355 g) obtained from Harlan Industries (Indianapolis, IN). They were housed individually in a colony that
was on a 12-h light/dark cycle. Experiments were conducted
during the light phase of this cycle. The rats had free access
to food and water while in the home cage. Each rat was handled for 1 min on at least 2 days prior to the start of an experiment. We minimized handling experience given the evidence
indicating that too much exposure to the experimental protocol could alter individual differences; this alteration is likely
due to shifts in sensitivity to mild stressors like exposure to a
novel environment (cf. Ref. [9]).
1.2. Drugs
( –)-Nicotine-di-D tartrate, mecamylamine hydrochloride (Research Biochemicals International, Natick, MA), and
hexamethonium bromide (Sigma, St. Louis, MO) were mixed
in saline (0.9% NaCl). The pH of nicotine was brought to 7.0
± 0.1 with a dilute sodium hydroxide solution. Dosages were
based on the salt form of the drug and injections were subcutaneous at a volume of 1 ml/kg.
1.3. Apparatus
Activity was automatically recorded in one of eight circular chambers made from white PVC pipe. The inside diameter
of each chamber was 30.5 cm and the top edge of the chamber was 45 cm from the wire mesh floor. Each chamber was
equipped with two infrared emitter/detector units. The infrared units were mounted 4 cm above the mesh floor such that
the chamber was divided into four equal sections. Each time the
rat broke the infrared beam, a count was automatically sent to
an interface and then recorded by a personal computer. Activity was defined as the number of infrared beam breaks in predetermined time intervals. The chambers were located in a room
adjacent to the animal colony. Fluorescent ceiling lights provided general illumination and a continuous white noise served to
mask external sounds.
1.4. Procedure
1.4.1. Mecamylamine
Rats were assigned to one of four conditions (16 rats per condition) before baseline activity in the novel chambers was assessed.
Novelty-induced activity for 36 rats was obtained on Day I. Each
rat was injected subcutaneously with saline and then placed in a
circular chamber where activity was monitored for 1 h. The remaining 28 rats were screened for baseline activity on Day 2. All
rats stayed in their home cages on Day 3. Starting on Day 4, each
rat received two injections before placement in the chamber. Two
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sets of rats received a subcutaneous injection of mecamylamine
(0.1 or 1.0 fig/kg) 15 min before an injection of 1 mg/kg ( –)-nicotine-di-D tartrate (0.351 mg/kg free base). Immediately after the
nicotine injection, rats were placed in the locomotor chambers
where activity was monitored for 30 min. A third set was treated similarly except the mecamylamine injection was replaced by
a saline injection. The last set of rats received saline for both injections. This latter set provided a no-drug baseline for comparison. The procedures of Day 4 were repeated once daily for seven
trials. On Day 11, all rats received a subcutaneous injection of ( –
)-nicotine-di-D tartrate (1 mg/kg) immediately before placement
in the chamber; the pretreatment injection was precluded on this
nicotine-alone test day.
1.4.2. Hexamethonium
Mecamylamine blocks central and peripheral nACh receptors [21]. To determine the contribution of peripheral vs. central nACh receptors to any individual differences effect, we
conducted an additional experiment in which rats were pretreated with the peripheral nACh antagonist hexamethonium [2]. The four conditions (18 rats per condition except the
saline-treated control had 16 rats) and the procedural details
were similar to the mecamylamine experiment except that
hexamethonium (5 or 10 fig/kg) replaced mecamylamine and
was injected subcutaneously 20 min before the ( –)-nicotinedi-D tartrate injection (cf. Ref. [7]). Also, the day intervening between the screen for novelty baseline and the first day
of nicotine treatment (i.e., Day 3) was eliminated. Rats had
served in an unrelated experiment; they were drug naive and
had never experienced the circular locomotor chambers.
1.5. Data analysis
1.5.1. Overall activity
To allow comparison with the published literature in this
area, we report overall activity counts (i.e., beam breaks) for
each experiment. Initial omnibus analyses were analysis of
variance (ANOVA); two-way repeated measure for Trials
1–7 data and a one-way ANOVA for the nicotine-alone test.
Post hoc tests, prompted by a significant effect, were used
to determine the source of the differences. Statistical significance was set at a two-tailed alpha of .05. If a post hoc contrast was not described, then the comparison was not statistically significant.
1.5.2. Individual differences
The main goal of the present report was to determine
whether novelty-induced activity predicted subsequent effects of nicotine and whether the antagonist mecamylamine
or hexamethonium altered these effects in a systematic manner. For each condition, we converted the total number of
beam breaks during the 1-h exposure to the novel chamber
to a z-score. We then divided rats in each condition into two
groups. Rats with positive z-scores (upper portion of the ac-

tivity distribution) were designated as HR; rats with negative
z-scores were designated LR. We then examined whether HR
and LR differed on Trial 1, Trial 7, or the nicotine-alone test.
Importantly, activity on these days was also converted to zscores before comparing HR and LR statistically with pairwise t tests. By normalizing the activity data with a z-score
conversion before analyses, we could determine whether HR
and LR on novelty-induced activity changed their relative position in the distribution across experimental treatment. That
is, regardless of whether locomotor activity was suppressed
or inflated relative to inescapable novelty, all the distributions had a mean of 0 and a standard deviation of 1. Thus,
would rats in the positive portion of the z-distribution during
the inescapable novelty screen (i.e., HR) remain in the upper
portion across repeated nicotine treatment? If so, this result
would indicate that reactivity to novelty predicts nicotine-induced activity.
2. Results
2.1. Overall activity
2.1.1. Mecamylamine
Activity in the inescapable novel environment did not differ across the four drug conditions, F < 1 (data not shown).
Fig. 1A shows the activity counts (number of infrared beam
breaks) across the first seven trials. On Trial 5, there was a
misalignment of an emitter/detector unit. Rather than using estimation procedures to fill in the missing counts for
these rats, we dropped this trial from the analyses and figure. There was a significant effect of drug condition (F(3,
60) = 3.23, P < .05], of trial (F(5, 300) = 22.05, P < .001]
and a significant Condition × Trial interaction (F(15, 300)
= 15.27, P < .001 ]. Post hoc LSD tests revealed that relative to the no-drug control (0Mec/0Nic), rats treated with
only nicotine (0Mec/1Nic) showed a significant decrease in
activity on the first trial. Mecamylamine completely blocked
this acute suppressive effect of nicotine. In fact, rats treated
with the high dose of mecamylamine (1Mec/1Nic) increased
activity above the no-drug control on Trial 1Mec/1Nic was
statistically similar to the control. In contrast, the nicotinealone group (0Mec/1Nic) and the group pretreated with the
low dose of mecamylamine (0.1Mec/1Nic) displayed an increase in activity across trials. Group 0Mec/1Nic was significantly more active than the control group on Trials 3–7.
Group 0.1Mec/1Nic was more active than controls on Trials
2–7; this group also differed significantly from Group 0Mec/
1Nic on Trial 2. Finally, Groups 0Mec/1Nic and 0.1Mec/
1Nic were significantly more active than Group 1Mec/1Nic
on the last two trials. In short, pretreatment with mecamylamine blocked nicotine-induced locomotor suppression (0.1
and 1 mg/kg mecamylamine); the high dose of mecamylamine (1 mg/kg) also blocked the subsequent locomotor-activating effects of nicotine.
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2.1.2. Hexamethonium
Novelty-induced activity did not differ statistically across
the four conditions, F < 1 (data not shown). Fig. 2A shows
the activity counts for each condition across the first seven trials. There was a significant effect of trial [F(6, 396) =
50.20, P < .001], and a significant Condition × Trial interaction [F(18, 396) = 18.41, P < .001]. The main effect of dose
was not significant [F(3,66) = 1.00, P = .399]. LSD tests revealed that activity was suppressed by nicotine on the first
trial regardless of the hexamethonium dose. However, the
high dose of hexamethonium (10Hex/1Nic) partially blocked
this suppressant effect. Group 10Hex/1Nic was more active
than the other two groups treated with nicotine. On Trial 2,
significant suppression relative to the no-drug control was
seen in rats receiving nicotine alone (0Hex/1Nic) or the low
dose of hexamethonium (5Hex/1Nic) but not in the rats pretreated with 10 mg/kg hexamethonium. Group 10Hex/1Nic
was more active than the nicotine-alone group on Trial 2. Finally, all groups were significantly more active than the nodrug control on Trials 4–7.

Fig. 1. Panel A shows the mean level of activity (± 1 S.E.M.) across the seven trials for each drug condition in the mecamylamine experiment. The number before the letter in group names denotes the dose of drug in milligrams
per kilogram [Mec = mecamylamine and Nic = ( –)-nicotine-di-D tartrate].
Panel B shows the mean activity level during the nicotine-alone test for each
drug condition in the mecamylamine experiment. Asterisks denote a significant difference (P < .05) from the no-drug control (0Mec/0Nic).

Fig. 1B shows the overall activity counts in the nicotine-alone
test for each group (i.e., Day 11 ). Recall that all rats received
an injection of ( –)-nicotine-di-D tartrate (1 mg/kg) immediately before placement in the locomotor chambers; mecamylamine injections were withheld on this day. The ANOVA revealed a significant effect of drug condition [F(3,60) = 40.31, P
< .001]. Post hoc tests comparing each group with the no-drug
control (0Mec/0Nic) found that Group 0Mec/1Nic was significantly more active. This result is not surprising considering that
this test reflects the first nicotine injection for the control group
(i.e., acute locomotor suppression by nicotine). Rats previously treated with the low dose of mecamylamine (0.1Mec/1Nic)
were also more active than the no-drug control group. However, rats 7 previously treated with the high dose of mecamylamine (1Mec/1Nic) did not differ from controls (0Mec/0Nic).
Thus, in a nicotine-alone test, previous pretreatment with the
high dose of the nACh receptor antagonist mecamylamine completely blocked tolerance to the suppressant effects of nicotine.
That is, even though rats in Group 1Mec/1Nic had seven previous injections of nicotine, their locomotor behavior was comparable to rats that had never received nicotine before this test.

Fig. 2. Panel A shows the mean level of activity (± 1 S.E.M.) across the seven trials for each drug condition in the hexamethonium experiment. The number before the letter in group names denotes the dose of drug in milligrams
per kilogram [Hex = hexamethonium and Nic = ( –)-nicotine-di-D tartrate].
Panel B shows the mean activity level during the nicotine-alone test for each
drug condition in the hexamethonium experiment. Asterisks denote a significant difference (P < .O5) from the no-drug control (0Hex/0Nic).
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Fig. 3. Panel A shows the mean z-score (± 1 S.E.M.) on Trial 1, Trial 7, and the nicotine-alone test for saline control rats classified as HR and LR based on activity induced by a novel environment. Rats in the saline controls from the mecamylamine (0Mec/0Nic) and the hexamethonium (0Hex/0Nic) experiments were pooled
into one large group. Panel B displays the mean z-score on Trial 1, Trial 7, and the nicotine-alone test for HR and LR in the groups treated with only nicotine (Groups
0Mec/1Nic and 0Hex/1Nic). Panel C shows the mean z-scores for HR and LR pretreated with the 1-mg/kg dose of mecamylamine before each of the seven trials of
nicotine administration (Group 1Mec/1Nic). Panel D shows the mean z-scores for HR and LR pretreated with the 10-mg/kg dose of hexamethonium before each of
the seven trials of nicotine administration (Group 10Hex/1Nic). Asterisks denote a significant difference (P < .05) from the comparable LR group.

Fig. 2B shows the activity counts for each group in the nicotine-alone test. That is, hexamethonium was withheld and all
rats received a 1-mg/kg injection of ( –)-nicotine-di-D tartrate
immediately before locomotor testing. Cotreatment of hexamethonium and nicotine did not appear to alter the subsequent
psychomotor effects of nicotine alone. The ANOVA revealed
a significant effect of group [F(3, 66) = 26.09, P < .001]. Contrasts revealed that all groups previously treated with nicotine
were more active than the no-drug control (0Hex/0Nic) which
was treated with nicotine for the first time on this day.
2.1.3. Individual differences
The mecamylamine and the hexamethonium experiments
included a set of rats that received only saline for the 7 days
following exposure to an inescapable novel environment
(Groups 0Mec/0Nic and 0Hex/0Nic). To increase the power of our individual differences analyses, we pooled the two
sets into one large group (n = 32) before converting the activity data for inescapable novelty, Trial 1, Trial 7, and the nicotine-alone test to z-scores and splitting the rats into HR and
LR based on performance during inescapable novelty (see
Fig. 3A). On Trials 1 and 7, HR had significantly higher zscores than LR [t(30) ≥ 2.17, P ≤ .038]. This data pattern indicates that saline control rats retained their relative position
in the distribution even though overall activity was decreasing across trials (i.e., environmental familiarization). Interestingly, initial exposure to nicotine on the test day disrupted this
difference, t < 1. Analysis of the pooled data for rats that received only nicotine (Groups 0Mec/1Nic and 0Hex/1Nic; n =

34) confirmed this effect of nicotine administration (see Fig.
38). HR did not differ statistically from LR on any day [t(32)
≤ 1.52, P ≥ .139, indicating that nicotine, whether a locomotor
suppressant (Trial 1) or a stimulant (Trial 7 and test), disrupted individual differences.
Fig. 3C shows the individual differences data for rats pretreated with the 1-mg/kg dose of mecamylamine before each
of the seven trials of nicotine administration (Group 1Mec/
1Nic). Mecamylamine restored the individual differences that
were disrupted by nicotine alone (Groups 0Mec/1Nic and
0Hex/1Nic). HR were significantly greater than LR on Trials
1 and 7 [t(14) ≥ 2.88, P ≤ .012], indicating rats classified in
the upper portion of the activity distribution during inescapable novelty remained there when mecamylamine was administered before nicotine. Again, nicotine alone on the test day
disrupted the difference between HR and LR [t(14) = 1.25, P
= .233]. Unlike mecamylamine, hexamethonium (10 mg/kg)
did not reinstate individual differences disrupted by nicotine
(see Fig. 3D). HR and LR were statistically similar on Trial 1,
Trial 7, and on the nicotine-alone test day [t(16) ≤ 1.85, P ≥
.083]. The data from the intermediate doses of mecamylamine
(0.1 mg/kg) and hexamethonium (5 mg/kg) are not shown because they are similar to the nicotine-alone condition and thus,
do not add to the conclusions.
3. Discussion
Previous research has shown that acute treatment with
nicotine can suppress locomotor activity in rats [7,36,37].
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Depending on the conditions of the experiment, this suppression can be quickly replaced by locomotor-activating effects
[7,19,20]. We replicated this activity pattern in the present set of experiments. Between-subject measures of activity (number of infrared beam breaks) revealed that 1 mg/kg
( –)-nicotine-di-D tartrate (0.351 mg/kg free base) initially
suppressed locomotor activity relative to saline-treated rats.
By the fourth nicotine administration, activity counts were
above control levels.
One goal of the present study was to determine whether the
initial locomotor-activating effects of novelty would be related
to rats’ subsequent sensitivity to the psychomotor effects of nicotine. Previous research has found that novelty-induced activity
can serve as a predictive variable for a rat’s sensitivity to the behavioral effects of abused drugs. This list of behaviors includes
self-administration [14,15,29], drug discrimination [13], context conditioning [17], bar-press suppression [6], and locomotor
activity [16,29]. Much of the research just cited reports a positive relation between reactivity to novelty and the subsequent
behavioral effect of interest. In contrast, we found that nicotine
disrupted individual differences that were present in saline controls. That is, HR to the first exposure to an environment (i.e.,
inescapable novelty) remained more active, in general, than LR
even after repeated exposure to the environment. Nicotine administration (acute and chronic) disrupted this difference. Nicotine-induced activity for some LR was now in the upper half
of the sampling distribution, whereas activity of some HR shifted to the lower half of the distribution. Nicotine-induced disruption of individual differences occurred regardless of whether nicotine was evoking locomotor suppression (e.g., Trial 1) or
locomotor stimulation (e.g., Trial 7).
Our conclusion appears to be in direct contrast to that of
previous individual differences research with nicotine (e.g.,
Ref. [34]). In that research, rats more activated by a novel environment (HR) were more sensitive to the locomotor-suppressant effects of nicotine, whereas LR were more sensitive to the
stimulant effects of nicotine. It is important to note that these
conclusions were based on measures and statistical comparisons
that were susceptible to a baseline-dependency interpretation
[11,28] .That is, HR may have shown greater sensitivity to the
locomotor-suppressant effects of nicotine simply because activity in this subset of rats was initially higher. Similarly, LR likely
displayed a larger relative increase in activity because their activity was initially lower. Indeed, if we assess individual differences using a within-subject shift in activity measure (i.e., nicotine-induced activity minus novelty-induced activity for the
comparable time period), we observe an effect similar to past research [34,35]. For example, on Trial 1 (acute nicotine), HR that
received only nicotine treatment displayed a significantly larger decrease in activity (–227 ± 17) than LR (–133 ± 17). Our
chronic nicotine data ( e.g., Trial 7) is also consistent with past
research. According to a shift measure, LR treated chronically
with nicotine were significantly more sensitive to the activating
effects of chronic nicotine (62 ± 16) than HR (–23 ± 17). Importantly, although the shift measures differed statistically, overall
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activity for HR and LR (number of infrared beam breaks) after
acute and chronic administration of nicotine did not differ significantly (Trial 1: HR = 179 ± 18, LR = 152 ± 10; Trial 7: HR =
382 ± 21, LR = 347 ± 12). This latter result is consistent with the
z-score analyses; nicotine disrupts predictable individual differences in activity that are present in a drug-free state.
We found that mecamylamine (1 mg/kg) completely prevented the acute suppressant and chronic activating effects of
nicotine [7,26,37]. The peripheral nACh receptor antagonist
hexamethonium, in contrast, did not block the chronic psychomotor effects of nicotine [5,7]. Interestingly, the low and
high dose of mecamylamine (0.1 and 1 mg/kg) blocked nicotine-induced locomotor suppression. Unlike the high dose,
however, the low dose of mecamylamine did not prevent the
chronic stimulant effects of nicotine. Whether this difference
in blockade reflects differential sensitivity to mecamylamine
blockade or differences in selectivity of the low and high
dose of mecamylamine requires further empirical attention.
Further, we found that the 10-mg/kg dose of hexamethonium
partially blocked the acute locomotor-suppressant effect of
nicotine. This result may indicate that nicotine-induced locomotor suppression is partially mediated by peripheral nACh
receptors or that some hexamethonium at this relatively high
dose was able to cross the blood/brain barrier and block central nACh receptors.
A second major goal of the present series of experiments
was to determine if individual difference effects induced by
nicotine were altered by mecamylamine or hexamethonium.
Pretreatment with hexamethonium did not alter nicotine disruption of individual differences. In contrast, mecamylamine
(1 mg/kg) restored individual differences. That is, rats which
were classified as HR based on activity in a novel environment remained HR when treated with mecamylamine 15 min
before administration of ( –)-nicotine-di-D tartrate. Similarly, LR remained in the lower portion of the distribution given mecamylamine pretreatment. For several reasons, these
results are especially interesting. First, this data pattern indicates that nicotine disrupts individual differences in activity via a centrally mediated process (i.e., neural nACh receptors). Second, and perhaps more interesting, is that these
results suggest that mecamylamine does not merely make
the average activity level of the group similar to saline controls. Rather, mecamylamine restores the animal’s activity
level back to its place in the group’s distribution—as if nicotine had not been administered.
Corroborating this latter suggestion are the results of the
nicotine-alone test. Recall that some rats were treated with
nicotine and mecamylamine daily for seven trials. Trial 8
was a test in which mecamylamine was withheld but all rats
were treated with 1 mg/kg ( –)-nicotine-di-D tartrate just before locomotor testing. In this nicotine-alone test, rats previously treated with the high dose of mecamylamine (1 mg/
kg) were as sensitive to the locomotor-suppressant effects
of nicotine as saline controls receiving nicotine for the first
time. Thus, chronic treatment of mecamylamine preceding
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nicotine did not alter sensitivity to nicotine-induced locomotor suppression. This conclusion is further supported by
the clear nicotine disruption of individual differences once
mecamylamine pretreatment was withheld (Fig. 3C). Finally,
previous experience with hexamethonium did not affect performance in the nicotine-alone test, thus indicating the importance of central nACh receptors.
In sum, rats that were more active during initial exposure
to an environment remained more active even after seven additional 30-min exposures to the same environment. Nicotine
treatment disrupted this effect. This nicotine disruption of individual differences occurred whether nicotine suppressed or
stimulated locomotor activity. Mecamylamine, but not hexamethonium restored the nicotine-induced disruption of individual differences. This result suggests that the effects of nicotine
on individual differences were mediated by neural nACh receptors. Further research in understanding individual differences and the effects of nicotine will be important given the current search for pharmacotherapies for smoking cessation using
nicotine and nACh receptor antagonists like mecamylamine (
e.g., Ref. [32]). Humans clearly show individual differences in
response to nicotine (e.g., Refs. [18,22,27]). Notably, not every person exposed to nicotine via smoking tobacco becomes a
chronic smoker [22]. Some people will attempt to smoke once
or twice and never try again, whereas other individuals will develop an abuse pattern, smoking up to several packs of cigarettes a day. By determining predictors of individual vulnerability to drugs of abuse or to pharmacotherapies meant to prevent
relapse, researchers and practitioners may be able to develop
better prevention and intervention strategies [12].
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